$0.4891
0.024.84%
At close: -
$0.4647
-0.02-4.99%
After Hours: 4:22 PM EDT
Comments
Loading...
Verrica Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRCA | Benzinga
Verrica Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Verrica Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
TD Cowen
Needham
Jefferies
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Verrica Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | Hold → Hold | Get Alert |
| 04/08/2025 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | — | Reiterates | Neutral → Neutral | Get Alert |
| 03/12/2025 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | Hold → Hold | Get Alert |
| 12/20/2024 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | Hold → Hold | Get Alert |
| 11/06/2024 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/05/2024 | Buy Now | — | Needham | Serge Belanger67% | — | Reiterates | → Hold | Get Alert |
| 11/05/2024 | Buy Now | — | RBC Capital | Gregory Renza47% | $11 → $2 | Downgrade | Outperform → Sector Perform | Get Alert |
| 10/21/2024 | Buy Now | — | TD Cowen | Stacy Ku21% | $15 → $10 | Maintains | Buy | Get Alert |
| 10/04/2024 | Buy Now | — | RBC Capital | Gregory Renza47% | $13 → $11 | Maintains | Outperform | Get Alert |
| 10/03/2024 | Buy Now | — | Needham | Serge Belanger67% | → $12 | Downgrade | Buy → Hold | Get Alert |
| 10/02/2024 | Buy Now | — | Brookline Capital | Kemp Dolliver27% | — | Downgrade | Buy → Hold | Get Alert |
| 08/15/2024 | Buy Now | — | RBC Capital | Gregory Renza47% | $14 → $13 | Maintains | Outperform | Get Alert |
| 08/15/2024 | Buy Now | — | Needham | Serge Belanger67% | $16 → $12 | Maintains | Buy | Get Alert |
| 05/16/2024 | Buy Now | — | Needham | Serge Belanger67% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | $13 → $14 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | — | Needham | Serge Belanger67% | $8 → $16 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | — | Needham | — | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | — | Needham | Serge Belanger67% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | $12 → $13 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | — | Jefferies | Glen Santangelo51% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/10/2023 | Buy Now | — | Needham | Serge Belanger67% | $10 → $8 | Maintains | Buy | Get Alert |
| 10/12/2023 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | — | Needham | Serge Belanger67% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | — | Needham | Serge Belanger67% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | $11 → $12 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | — | RBC Capital | Gregory Renza47% | $11 → $14 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | — | Needham | Serge Belanger67% | → $10 | Upgrade | Hold → Buy | Get Alert |
| 07/17/2023 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2023 | Buy Now | — | Jefferies | Glen Santangelo51% | → $10 | Initiates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | — | RBC Capital | Gregory Renza47% | → $11 | Reiterates | → Outperform | Get Alert |
| 02/13/2023 | Buy Now | — | RBC Capital | Gregory Renza47% | $4 → $11 | Upgrade | Sector Perform → Outperform | Get Alert |
| 05/31/2022 | Buy Now | — | HC Wainwright & Co. | Oren Livnat61% | $20 → $12 | Maintains | Buy | Get Alert |
| 05/25/2022 | Buy Now | — | RBC Capital | Daniel Busby35% | $16 → $4 | Downgrade | Outperform → Sector Perform | Get Alert |
FAQ
What is the target price for Verrica Pharmaceuticals (VRCA) stock?
The latest price target for Verrica Pharmaceuticals (NASDAQ:VRCA) was reported by Needham on April 9, 2025. The analyst firm set a price target for $0.00 expecting VRCA to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verrica Pharmaceuticals (VRCA)?
The latest analyst rating for Verrica Pharmaceuticals (NASDAQ:VRCA) was provided by Needham, and Verrica Pharmaceuticals reiterated their hold rating.
When was the last upgrade for Verrica Pharmaceuticals (VRCA)?
The last upgrade for Verrica Pharmaceuticals Inc happened on July 25, 2023 when Needham raised their price target to $10. Needham previously had a hold for Verrica Pharmaceuticals Inc.
When was the last downgrade for Verrica Pharmaceuticals (VRCA)?
The last downgrade for Verrica Pharmaceuticals Inc happened on November 6, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Verrica Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Verrica Pharmaceuticals (VRCA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verrica Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verrica Pharmaceuticals was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating Verrica Pharmaceuticals (VRCA) correct?
While ratings are subjective and will change, the latest Verrica Pharmaceuticals (VRCA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Verrica Pharmaceuticals (VRCA) is trading at is $0.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
